| Entry |
|
|---|
| Name |
Amplified MET to PI3K signaling pathway
|
|---|
| Definition |
MET* -> GAB1 -> PI3K -> PIP3 -> AKT -> MTOR |
|---|
| Expanded |
4233v3 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
|
|---|
| Gene |
| 4233 | MET; MET proto-oncogene, receptor tyrosine kinase |
| 2549 | GAB1; GRB2 associated binding protein 1 |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 2475 | MTOR; mechanistic target of rapamycin kinase |
|
|---|
| Variant |
4233v3 (MET*) MET amplification
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Appleman LJ |
|---|
| Title |
MET signaling pathway: a rational target for cancer therapy. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Feng Y, Ma PC |
|---|
| Title |
Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Kawakami H, Okamoto I |
|---|
| Title |
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
